Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Between October 1 and October 2, 2026, four biotechnology companies—Taysha Gene Therapies, Alpha Cognition, Xenon Pharmaceuticals, and Rigel Pharmaceuticals—announced equity inducement grants for new employees supporting clinical development and commercialization efforts.
- Each company issued stock options and restricted stock units under Nasdaq Listing Rule 5635, a provision allowing equity awards as inducement material to individuals entering employment with the company.
- Xenon granted 17,850 options and 10,500 RSUs to eight employees; Taysha awarded 92,400 options and 384,000 RSUs to four staff, while Rigel provided 35,275 RSUs to 18 workers and Alpha Cognition granted 6,000 options to one.
- Alpha Cognition maintains strategic focus on developing treatments for neurodegenerative diseases including Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury, with pipeline candidates ZUNVEYL and ALPHA-1062.
- Inducement grants serve to attract essential talent for Xenon and Taysha as they advance gene therapy and neuroscience-focused clinical programs addressing severe unmet medical needs in patients.
16 Articles
16 Articles
St Catharines Standard
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants…
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors…
Hastings Tribune
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today…
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
